Welichem Biotech Inc. Completes Phase IIa Clinical Trial on Eczema

Published: Jun 20, 2008

BURNABY, BC, June 19 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX- V: WBI), a biotechnology company developing therapeutic drugs for the treatment of anti-inflammatory and auto-immune diseases and cancer, is pleased to announce that the clinical component of a Phase IIa trial on Atopic Dermatitis (a form of eczema) has been completed. The final report on this randomized, double-blinded, vehicle-controlled study to evaluate the safety, tolerability and efficacy of topically applied WBI-1001 cream in subjects with Atopic Dermatitis (AD) is expected later this summer.

Back to news